Home Blog of Signal Transduction Transmembrane Transporters CRM1

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

CRM1

Exportin-mediated nucleocytoplasmic transport maintains Pch2 homeostasis during meiosis

109 views | Feb 04 2024

The intricate interplay between the AAA+ ATPase Pch2, Crm1 exportin-mediated nucleocytoplasmic transport, and the identification of a specific Nuclear Export Signal within Pch2 unveils a crucial regulatory mechanism governing its cellular distribution and function during meiosis. [Read the Full Post]

Heat stress upregulates aromatases expression through nuclear DAX-1 deficiency in R2C Leydig tumor cells

104 views | Dec 19 2023

Heat stress at 40 °C was found to increase aromatase expression in Leydig cells, leading to a decreased testosterone to estradiol ratio, potentially impacting spermatogenesis, with the mechanism involving interference with the DAX-1-SF-1 interaction and induction of SF-1-dependent aromatase transcription. [Read the Full Post]

Assessment of verdinexor as a canine P-glycoprotein substrate

114 views | Oct 20 2023

Verdinexor has been determined to not be a substrate for canine P-gp based on cytotoxicity and competitive flow cytometry assays using a cell line overexpressing canine P-gp. [Read the Full Post]

Identification of Piperlongumine as Potent Inhibitor of Necroptosis

259 views | Jun 14 2023

Piperlongumine, an alkaloid derived from the long pepper plant, has demonstrated potent anti-necroptosis effects by inhibiting the phosphorylation of RIPK1 and showed potential therapeutic value for inflammatory and neurodegenerative diseases associated with necroptosis. [Read the Full Post]

The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-κB/NLRP3 Pathway

113 views | Oct 19 2022

Shuhan Liu et al. indicated that KPT-8602 could be used as a novel potential therapeutic agent for the treatment of inflammasome-related diseases such as Parkinson's disease, through the regulation of the NF-κB signaling pathway and the NLRP3 inflammasome. [Read the Full Post]

Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide

114 views | Oct 18 2022

Katharina Otte et al. concluded that monotherapy with Eltanexor effectively induced apoptosis in GBM cells and could be combined with current adjuvant therapies to provide a more effective therapy of GBM. [Read the Full Post]

Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series

256 views | Jul 15 2022

Guillermina Remaggi et al. thought that selinexor might help to address an important clinical need in the treatment of patients with relapsed/refractory MM. [Read the Full Post]

Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells

163 views | Jul 14 2022

Amal Alzahrani et al. confirmed that the combination of Selinexor with RG-7388 could induce a caspase-mediated apoptotic mechanism via up-regulation of p53 and p21. [Read the Full Post]

PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia

374 views | Nov 25 2021

Inge Govaerts et al. thought that the antileukemic effect of PSEN1-selective gamma-secretase inhibition could be synergistically enhanced by the addition of other targeted inhibitors. [Read the Full Post]

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells

0 views | Nov 24 2021

Md Hafiz Uddin et al. found that KPT-8602 with or without olaparib reduced homologous recombination-regulated DNA damage response targets including BRCA1, BRCA2, CHEK1, EXO1, BLM, RAD51, LIG1, XRCC3 and RMI2. [Read the Full Post]